Difference between revisions of "Camrelizumab (AiRuiKa)"
(Created page with "==Mechanism of action== From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/camrelizumab NCI Drug Dictionary]: A monoclonal antibody directed against th...") |
m |
||
| Line 1: | Line 1: | ||
==Mechanism of action== | ==Mechanism of action== | ||
From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/camrelizumab NCI Drug Dictionary]: A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1,) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, camrelizumab binds to and blocks the binding of PD-1, expressed on activated T lymphocytes, B cells and natural killer (NK) cells, to its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen presenting cells (APCs). This prevents the activation of PD-1 and its downstream signaling pathways. This restores immune function through the activation of cytotoxic T lymphocytes (CTLs) and cell-mediated immune responses against tumor cells or pathogens. | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/camrelizumab NCI Drug Dictionary]: A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1,) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, camrelizumab binds to and blocks the binding of PD-1, expressed on activated T lymphocytes, B cells and natural killer (NK) cells, to its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen presenting cells (APCs). This prevents the activation of PD-1 and its downstream signaling pathways. This restores immune function through the activation of cytotoxic T lymphocytes (CTLs) and cell-mediated immune responses against tumor cells or pathogens. | ||
| + | |||
| + | ==Diseases for which it is used== | ||
| + | *[[Esophageal squamous cell carcinoma]] | ||
==Also known as== | ==Also known as== | ||
| Line 9: | Line 12: | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
[[Category:Anti-PD-1 antibodies]] | [[Category:Anti-PD-1 antibodies]] | ||
| + | |||
| + | [[Category:Esophageal squamous cell carcinoma medications]] | ||
| + | |||
[[Category:CFDA approved drugs]] | [[Category:CFDA approved drugs]] | ||
Revision as of 18:03, 5 June 2021
Mechanism of action
From the NCI Drug Dictionary: A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1,) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, camrelizumab binds to and blocks the binding of PD-1, expressed on activated T lymphocytes, B cells and natural killer (NK) cells, to its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen presenting cells (APCs). This prevents the activation of PD-1 and its downstream signaling pathways. This restores immune function through the activation of cytotoxic T lymphocytes (CTLs) and cell-mediated immune responses against tumor cells or pathogens.
Diseases for which it is used
Also known as
- Code names: HR-301210, SHR-1210
- Brand name: AiRuiKa